Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ulipristal - HRA Pharma

Next Previous
Drug Profile

Ulipristal - HRA Pharma

Alternative Names: CDB-2914; ella; ellaOne; Esmya; Fibristal; HRP 2000; PGL-4001; RTI 3021-12; RU 44675; Ulipristal acetate; UPA; UPA C-IUS; UPA C-ring; UPA-IUS; UPA-UF; UPA-VR; VA-2914

Latest Information Update: 10 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HRA Pharma; National Institutes of Health (USA)
  • Developer AbbVie; ASKA Pharmaceutical; Gedeon Richter; HRA Pharma; Population Council (USA); PregLem
  • Class Antineoplastics; Norpregnadienes; Oral contraceptives; Small molecules
  • Mechanism of Action Selective progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Female genital diseases; Uterine leiomyoma

Highest Development Phases

  • Marketed Pregnancy; Uterine leiomyoma
  • Discontinued Breast cancer; Endometriosis; Menopausal syndrome

Most Recent Events

  • 10 Feb 2025 Planned Prescription Drug User Fee Act (PDUFA) date for Uterine leiomyoma in USA (PO) is 2018-08-31
  • 18 Jul 2024 Regulatory submission withdrawn for Uterine leiomyoma in European Union (PO)
  • 18 Jul 2024 European commission withdraws marketing approval for Uterine leiomyoma in European Union (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top